Browse Studies — Arctuva

Phase 1

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents …

NSCLC AdenocarcinomaGastroesophageal Cancer (GC)Gastric Adenocarcinoma+10 more

Estimated

~$10 – $8,750

IDEAYA BiosciencesNCT07277413

Phase 1

A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors

This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1…

Head and Neck Squamous Cell Carcinoma HNSCCNon-Small Cell Lung Cancer NSCLCEsophageal Cancer+6 more

Estimated

~$10 – $8,750

Sutro Biopharma, Inc.NCT07227168

Phase 3

A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based…

NSCLCNon-small Cell Lung CancerNon-Small Cell Lung Cancer NSCLC+4 more

Estimated

~$10 – $8,750

Revolution Medicines, Inc.NCT07777822